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Abstract
Objective: To date, biomarkers are not routinely used in endometrial cancer diagnosis, prognosis, and follow-up. The
purpose of this study was to evaluate whether serum HE4 was related to clinicopathological risk factors and outcome.
Second, the role of serum HE4 and CA125 was assessed as indicator for recurrent disease during follow-up.
Methods: A total of 174 patients with endometrial cancer between 1999 and 2009 were selected for this retrospective
study. Serum HE4 and CA125 were analyzed at primary diagnosis, during follow-up, and at the time of recurrence.
Correlations with clinicopathological factors were studied by univariate and multivariate survival analyses. Lead time
was calculated in order to determine which serum marker was elevated prior to clinical detection of recurrent disease.
Results: Serum levels of HE4 and CA125 were significantly associated with high tumor grade, myometrial invasion,
lymph node involvement, and advanced stage (p\ 0.01). HE4 was an independent prognostic factor for reduced
disease-free survival and overall survival with hazard ratios of 2.96 (95% confidence interval: 1.18–7.99) and 3.27 (95%
confidence interval: 1.18–9.02), respectively. At recurrence, 75% of the patients had an elevated HE4 compared to 54%
with an elevated CA125. HE4 levels were more frequently elevated in patients with distant metastasis compared to
local recurrences, 67% and 37%, respectively. Serum HE4 detected a recurrence with a median of 126 days earlier than
clinical confirmation.
Conclusion: Elevated serum HE4 is an independent risk factor for reduced disease-free survival and overall survival.
HE4 seems to be superior to CA125 in the detection of recurrent disease during follow-up, mainly in high-risk
endometrial cancer patients who are more prone to distant metastasis.
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Introduction
Endometrial cancer (EC) is the most common malig-
nancy of the female genital tract with an increasing
incidence.1 Since most patients present with symptoms
of postmenopausal or abnormal uterine bleeding, 80%
of the EC patients are diagnosed at an early stage and
have a favorable prognosis with a 5-year survival rate
around 80%–90%.2 Yet, 13%–17% of the EC patients
develop recurrent disease, mostly within 3 years of pri-
mary treatment.3 In case of an isolated recurrence at
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the vaginal vault, local treatment is often with curative
intent. For distant metastasis, treatment options are
limited and prognosis is poor.2,4,5
To date, follow-up consists of monitoring clinical
symptoms combined with gynecological examination,
yet it is known that 41%–83% of the recurrences are
symptomatic.4,5 In general, there is no consensus about
surveillance strategies. In patients with low-risk EC, the
added value of intensive surveillance has not been
demonstrated.4,5 Also for patients with high-risk EC,
with a significant risk of recurrence, it is not clear
whether intensive surveillance contributes to early
detection and/or an improved outcome. In addition to
clinical examination, cytology of the vaginal vault and
chest X-ray has been evaluated for the detection of
recurrent disease, both with a low detection rate.3
Imaging techniques such as ultrasound (US), com-
puted tomography (CT), magnetic resonance imaging
(MRI), and positron emission tomography (PET) can
be used in symptomatic patients to assess the extent of
the disease. Yet, routine use is not advocated because of
the low detection rate for recurrent disease and the fact
that imaging did not improve survival when compared
to clinical examination.3,5,6 Adding biomarkers to rou-
tine follow-up might be beneficial; although for CA125,
one of the most studied biomarkers in EC, the value
seems limited.7,8 Several studies have demonstrated the
correlation of elevated CA125 with advanced-stage dis-
ease and lymph node metastasis.9,10 However, the sensi-
tivity and specificity are poor, and therefore, CA125 is
not routinely used in clinical practice in the diagnostic
work-up of EC.7,8,11 Recent studies suggest a promising
role for human epididymis protein 4 (HE4) in the diag-
nostic work-up and follow-up of patients with
EC.9,12–14 The Australian National Endometrial Cancer
Study (ANECS) is the largest prospective study to date
which showed that HE4 was correlated with clinico-
pathological factors and demonstrated that HE4 was
an independent predictor of recurrence-free survival.15
HE4 belongs to the protease inhibitors and is loca-
lized in the epithelial cells of the epididymal duct.
However, expression also has been reported in a num-
ber of tissues outside the male reproductive system, as
well as in various types of carcinomas, including
EC.9,16,17 It is presumed that HE4 plays a role in natu-
ral immunity, yet little is known about its potential role
in carcinogenesis.18
There is accumulating evidence that HE4 is superior
to CA125 in the diagnostic work-up of EC in terms of
a higher sensitivity and specificity.9,19,20 To date, little
is known about the predictive value of HE4 and
CA125 to detect a recurrence. Angioli et al. reported
that preoperative HE4 levels were higher in patients
who developed a recurrence compared to patients with-
out recurrence. These data support the potential role of
HE4 in both the identification of high-risk patients and
in the detection of a recurrence.14,20 Brennan et al. also
showed that HE4 was a sensitive and specific predictor
of recurrent disease, particularly in patients with endo-
metrioid histology with an area under the curve (AUC)
of 0.87 compared to 0.67 for CA125.13
In a small series of ovarian cancer patients (n=23),
HE4 was superior to CA125 in the detection of a recur-
rence. In addition, increased serum levels of HE4 pre-
ceded the rise of CA125 by 4.5months.21 The aim of
our study was to compare the dynamic changes of serial
serum measurements of HE4 and CA125 in relation to
recurrent disease in EC patients.
Material and methods
Patients
A total of 174 patients who underwent primary surgical
treatment for EC at the Radboud University Medical
Center (Nijmegen) between 1999 and 2009 and from
whom preoperative serum was stored were selected for
this retrospective study. All endometrial histological
subtypes were included, whereas patients with progres-
sive disease were excluded.
Preoperative diagnosis was based on dilatation and
curettage (D&C) or Pipelle endometrial sampling. All
patients underwent at least an abdominal hysterectomy
and bilateral salpingo-oophorectomy. Surgical staging
with pelvic and/or para-aortic lymphadenectomy was
performed in patients with preoperative high tumor
grade. All patients were re-staged according the
International Federation of Gynecology and Obstetrics
(FIGO).22 Adjuvant radiotherapy was applied according
to the postoperative radiation therapy in endometrial
carcinoma (PORTEC) criteria (deep myometrial invasion
(MI), high tumor grade, and age .60years) for treat-
ment of stage I–II patients, and chemotherapy was admi-
nistered in patients with stage III–IV disease. Medical
records of the patients were carefully reviewed.23
Patients’ follow-up was performed from the date of
primary treatment until the last visit or death. For the
first 3 years, patients were seen every 3months and
every 6months afterwards till 5 years after diagnosis.
After 5 years of follow-up, patients were dismissed.
Recurrent disease was detected by radiological ima-
ging or confirmed by histological biopsy. The disease-
free interval had to be at least 3months after primary
treatment.24,25
The study was approved by the Ethics Committee of
the Radboud University Medical Center (Nijmegen).
Aims of the study
The primary aim of this study was to evaluate whether
serum HE4 and CA125 were related to clinicopatholo-
gical risk factors and outcome. Secondary aim was to
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compare serum HE4 and CA125 levels at the time of
recurrence and to assess their role as indicator of recur-
rent disease in serial serum measurements.
Serum storage
Blood samples were collected in dry tubes by vena
puncture and centrifuged at 2000g for 10min. Serum
was stored at 240C until analyzed.
HE4 and CA125 measurements
HE4 and CA125 serum levels were measured by the
LUMIPULSE chemiluminescent enzyme immunoassay
(CLEIA) kit according to the manufacturer’s (Fujirebio
Diagnostic, Inc., Malvern, PA, USA) instructions.26
Serum samples of four different time points were
used: (1) at primary diagnosis, (2) post-surgery, (3) fol-
low-up, and (4) at recurrence.
Statistical analysis
Statistical analysis was performed using GraphPad
prism version 5.3 (GraphPad Software, Inc., La Jolla,
CA, USA). In all tests, p\ 0.05 (two-sided) was con-
sidered to indicate statistical significance.
Serum concentrations of HE4 and CA125 were pre-
sented as median values, and log transformation was
applied because the distribution was positively skewed.
Clinical and pathological parameters of the non-
recurrence and recurrence groups were compared using
the Pearson x2 or Fisher exact test for categorical vari-
ables, also using the independent t-test or Mann–
Whitney-U test when appropriate.
Paired serum measurements were compared with the
Wilcoxon signed-rank test. The Cox-proportional
hazard model was used to assess the prognostic value of
serums HE4 and CA125 as log transformed continuous
factors, both in univariate and multivariate analyses.
Traditional prognostic factors such as FIGO stage, age,
tumor grade, MI, and lymphovascular space invasion
(LVSI) were included in a base model. HE4 and CA125
were entered separately in a second block. Points esti-
mated were reported as hazard ratios (HRs) and 95%
confidence intervals (CIs). Based on published data, the
used cut-off value for HE4 was 70 pmol/L and for
CA125 was 35U/mL.27–30
Recurrent disease was detected by radiological ima-
ging or confirmed by histological biopsy. The disease-free
period had to be at least 3months after primary treat-
ment. The time to recurrence was noted, and subse-
quently, the time between the rise of serum levels of HE4
and CA125 and recurrence was calculated. The time
between the elevation of serum markers and the recur-
rence was defined as the lead time to recurrence. The lead
time (days) was calculated for both HE4 and CA125.25
Results
Patients
A total of 174 patients with EC with available preo-
perative serum sample were analyzed. After review, 17
cases were excluded because of progressive disease after
primary diagnosis, resulting in 157 patients that could
be included in our study.
Baseline patients’ characteristics are demonstrated in
Table 1. Patients had a median age of 63years and a
body mass index (BMI) of 27kg/m2. In all, 48 (31%)
patients developed a recurrence, of which 40% (n=19)
was located in the pelvis (loco regional) and 60%
(n=29) outside the pelvis (distant recurrences). Patients
who developed recurrent disease were more likely to have
Table 1. Baseline patient characteristics.
N = 157 %
Age (years; median) 63 (56–71)
BMI (kg/m2; median) 27 (23–33)
Histology
Endometrioid 122 78
Non-endometrioid 35 22
FIGO
IA 17 10
IB 83 53
II 11 7
III 27 17
IV 19 13
Grade
I 27 17
II 71 45
III 59 38
LVSI
Yes 62 39
No 64 41
Missing 31 20
MI
\50% 74 48
50% 78 50
Missing 5 2
Lymph node involvement
Yes 13 25
No 39 75
Not assessed 105
Recurrence
Locoregional 19 40
Distant 29 60
None 109
Time to recurrence (median)
Locoregional 8 (5–18)
Distant 15 (5–30)
Overall survival (median)
Non-recurrence 67 (50–104)
Recurrence 24 (9–48)
LVSI: lymphovascular space invasion; MI: myometrial invasion; BMI: body
mass index; FIGO: International Federation of Gynecology and
Obstetrics.
Data are presented as numbers with percentage or as median with
range.
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FIGO stage III/IV disease, high tumor grade, and LVSI
(data not shown). There were no significant differences in
age, BMI, or tumor type between patients experienced a
recurrence and those who remained disease free. The
median overall survival (OS) of patients with recurrence
was 24months (9–48months) and without recurrence
was 67months (50–104months). Locoregional recur-
rences developed after a median of 8months, whereas dis-
tant recurrence developed after a median of 15months;
however, this was not significantly different.
Serum HE4 and CA125 in relation to
clinicopathological risk factors and outcome
In Table 2, clinicopathological factors in relation to
serum levels HE4 and CA125 are shown. Both serum
markers HE4 and CA125 were significantly related to
clinicopathological risk factors, such as FIGO stage,
LVSI, MI, and lymph node involvement.
HE4 and CA125 levels were higher in stage III/IV
disease, in the presence of LVSI, MI 50%, and lymph
node involvement. CA125 was significantly higher in
grade 3 and non-endometrioid histology, whereas HE4
levels were higher in patients 60 years. BMI was not
related with either HE4 or CA125 serum levels.
Unfortunately, we were not able to differentiate differ-
ent EC stages with serum HE4. However, HE4 has an
AUC of 0.72 to predict the involvement of lymph
nodes. Based on the receiver operating characteristic
curve (ROC) curve (Supplementary Figure 1), an HE4
cut-off of 130mmol/L reported the best performance in
terms of a sensitivity (65%) and a specificity (79%) to
correctly classify patients with positive lymph nodes.
HE4 and CA125 in relation to recurrence
Serum levels in relation to recurrence are shown in
Table 3, and serial measurements of HE4 and CA125
are illustrated in Figures 1 and 2. Preoperative serum
Table 2. Clinicopathological factors in relation to serum levels of HE4 and CA125.
HE4 p value CA125 p value
Age (years; median)
\60
60
60 (40–94) \0.01 15 (8–36) 0.28
90 (56–160) 17 (10–42)
BMI (kg/m2; median)
\25
25
75 (38–112) 0.45 16 (9–33) 0.90
73 (50–134) 16 (9–43)
Histology
Endometrioid 73 (46–124) 0.21 14 (7–27) \0.01
Non-endometrioid 79 (50–169) 28 (15–72)
FIGO
I–II 62 (45–101) 0.01 12 (8–22) \0.01
III–IV 79 (51–153) 17 (9–44)
Grade
I–II 69 (44–112) 0.05 13 (7–25) \0.01
III 81 (50–164) 25 (12–62)
LVSI
Yes 96 (57–169) \0.01 23 (11–66) \0.01
No 59 (37–86) 12 (8–21)
MI
\50% 59 (41–97) \0.01 12 (8–20) \0.01
50% 86 (57–156) 25 (14–57)
Lymph node involvement
Yes 153 (90–260) \0.01 41 (19–194) 0.03
No 68 (46–96) 19 (11–43)
LVSI: lymphovascular space invasion; MI: myometrial invasion; BMI: body mass index; FIGO: International Federation of Gynecology and Obstetrics.
Data are presented as medians with 25–75e percentile. HE4 (pmol/L) and CA125 (U/mL).
Table 3. HE4 and CA125 levels in relation to recurrence.
Non-recurrence Recurrence p value
N= 108 N=42
Median HE4
Diagnosis 68 (46–110) 86 (51–199) 0.015
Post-surgery 43 (32–66) 75 (30–152) 0.021
Follow-up 41 (29–75) 138 (59–340)
Recurrence N/A 235 (56–570) \0.001
Median CA125
Diagnosis 14 (8–27) 22 (10–83) 0.023
Post-surgery 8 (5–11) 22 (12–52) \0.001
Follow-up 7 (5–10) 37 (15–114)
Recurrence N/A 68 (16–221) \0.001
Data are presented as medians with 25–75e percentile. HE4 (pmol/L)
and CA125 (U/mL).
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levels of both HE4 and CA125 were significantly higher
in patients who experienced a recurrence than those
who remained disease free. HE4 levels were 86 and
63pmol/L (p=0.01) and 75 and 14U/mL (p=0.02)
for CA125, respectively.
In patients with recurrent disease, 75% (n=18) had
an elevated HE4 compared to 54% (n=13) with an
elevated CA125 (data not shown). With respect to the
location of a recurrence, only 39% (n=7) of the
patients with a local recurrence had elevated HE4 val-
ues compared to 16% (n=3) with an elevated CA125.
In patients with distant metastasis, elevated HE4 levels
were present in 67% (n=20) where only 55% (n=16)
had an elevated CA125 (data not shown).
Disease-free survival (DFS) was significantly associ-
ated with elevated HE4 and CA125 in the univariate
analysis. HRs were 4.23 (p\ 0.001) and 3.16
(p\ 0.001), respectively (Table 4).
Both HE4 and CA125 were significantly associated
with OS in the univariate analysis with HRs of 7.77
(p\ 0.001) and 3.41 (p\ 0.001), respectively.
Next to FIGO stage and age, HE4 showed to be the
strongest independent prognostic factor for OS fol-
lowed by CA125 with HR=3.27 (p=0.02) and
HR=2.14 (p=0.03), respectively.
With respect to serial measurements, we used four
different time points; median time between primary
diagnosis and post-surgery was 53 days (21–114 days)
and 55days (16–92days) between follow-up and
Figure 1. HE4 and CA125 in recurrent and non-recurrent patients with EC. Box plots display serum levels at different measure
points, demonstrating medians with interquartile range. HE4 levels of (a) patients with recurrence and (b) patients without
recurrence. CA125 levels of (c) patients with recurrence and (d) without recurrence.
Figure 2. Lead time of HE4. HE4 median values are depicted
for each time point (diagnosis, post-surgery, follow-up, and
recurrence). The arrow indicates the point where HE4 crosses
the cut-off levels with a median of 126 days before clinical
detection of recurrent disease.
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recurrence. At all serial measurements, serum levels of
both HE4 and CA125 were significantly higher in
patients who developed a recurrence compared to those
without recurrence. As illustrated in Figure 1, serum
levels of HE4 and CA125 remained low in the non-
recurrence group.
Figure 2 displays that serum levels of HE4 were sig-
nificantly increased at the follow-up moment prior to
the clinical detection of recurrent disease (p=0.042).
In contrast, increase in serum levels of CA125 was
minor and not significant.
The lead time for HE4 was calculated to determine
the time between elevation of the serum marker and
clinical detection of recurrent disease. Figure 2 displays
the median HE4 levels at the different serial
measurements.
The rise of HE4 above the used cut-off value
detected a recurrence with a median of 126 days earlier
than the clinical confirmation of recurrent disease (indi-
cated with black arrow in Figure 2).
Discussion
In this study, we showed that elevated serum levels of
HE4 and CA125 correlate with well-established prog-
nostic factors for EC, such as high tumor grade, MI,
lymph node involvement, LVSI, and advanced stage
and that elevated serum levels correlate with DFS and
Table 4. Hazard ratios of disease-free survival and overall survival.
Disease-free survival
Univariate Multivariate
HR 95% CI p value HR 95% CI p value
Base modela
FIGO stage 4.75 2.63–8.60 \0.01 3.63 1.84–7.15 \0.01
III–IV versus I–II
Age (years) 2.15 1.16–3.99 0.01 2.36 1.17–4.76 0.01
.60 versus <60
Grade 2.30 1.28–4.11 \0.01 1.63 0.84–3.16 0.15
III versus I–II
MI 1.53 0.81–2.87 0.18 0.99 0.50–1.98 0.98
.50% versus <50%
LVSI 2.36 1.23–4.52 \0.01 1.18 0.58–2.41 0.65
Yes versus no
Additions to model (all continuous, log transformed, and separately entered)
Serum HE4 4.23 2.02–8.82 \0.01 2.96 1.18–7.94 0.03
Serum CA125 3.16 1.95–5.12 \0.01 1.58 0.86–2.91 0.14
Overall survival
Univariate Multivariate
HR 95% CI p value HR 95% CI p value
Base modela
FIGO stage 5.75 3.19–10.34 \0.01 3.69 1.86–7.31 \0.01
III–IV versus I–II
Age (years) 2.19 1.19–4.06 0.01 2.37 1.18–4.78 0.02
.60 versus <60
Grade 3.42 1.92–6.10 \0.01 1.61 0.83–3.13 0.15
III versus I–II
MI 2.57 1.29–5.09 \0.01 1.01 0.51–2.02 0.96
.50% versus <50%
LVSI 2.08 1.10–3.94 0.02 1.15 0.56–2.40 0.69
Yes versus no
Additions to model (all continuous, log transformed, and separately entered)
Serum HE4 7.77 4.00–15.07 \0.01 3.27 1.18–9.02 0.02
Serum CA125 3.41 1.99–5.82 \0.01 2.14 1.09–4.20 0.03
MI: myometrial invasion; LVSI: lymphovascular space invasion; BMI: body mass index; FIGO: International Federation of Gynecology and Obstetrics;
CI: confidence interval.
aThe base model consisted of traditional prognostic factors, and we separately entered the parameters in a second block. The multivariate analysis
showed that besides FIGO stage and age, only HE4 turned out to be an independent prognostic factor for DFS with an HR of 2.96 (p = 0.03).
Bold values indicate the significant HR’s.
6 Tumor Biology
OS. During follow-up, serum levels of HE4 were super-
ior to CA125 with respect to identification of patients
with recurrence as well as the prediction of a recur-
rence. Preoperative measurement of serum HE4 levels
is superior to CA125 and could help to identify patients
at risk of advanced-stage disease, lymph node involve-
ment, and recurrence of disease. This might contribute
to a more personalized treatment and follow-up plan.
The results of our study showed that HE4 correlates
with well-known prognostic factors and are in line with
previous studies.9,10,12,15,20,28,31,32 Serum HE4 was cor-
related with FIGO stage, tumor grade, MI, and LVSI.
Although our cohort is relatively old in comparison
with other studies, cohort size was fairly similar.
Besides a correlation between HE4 and risk factors for
lymph node involvement, we found a direct correlation
between serum HE4 and the presence of lymph node
metastasis. However, results about lymph node invol-
vement and HE4 are still conflicting. A possible expla-
nation could be that other studies report low numbers
of performed lymphadenectomy, whereas median HE4
levels may not reach significance in patients with lymph
node involvement.9,12,32 In agreement with other stud-
ies, we did not observe a correlation between HE4 and
the different histological subtypes, but the number of
non-endometrioid EC in our cohort was relatively
small to draw final conclusion.20,32 Outcome in patients
with EC is mainly determined by clinicopathological
factors. As expected, clinicopathological factors were
significantly associated with OS in the univariate analy-
sis providing the validity of our patient cohort. Yet, in
this study, we observed that elevated HE4 was an inde-
pendent prognostic factor for both DFS and OS in
patients with EC which is in line with the recent studies
by Stiekema et al.32 and Mutz-Dehbalaie et al.33 The
ANECS confirmed these results in a prospective study
among 373 patients with EC. They showed that HE4
levels were higher in patients with an advanced FIGO
stage, and it was a better predictor of outer-half MI
than CA125. Besides this, it was shown that HE4 was
an independent predictor of recurrence-free survival.
To date, this is one of the few studies which demon-
strate the value of HE4 as an independent prognostic
factor for both DFS and OS in patients with EC.
With respect to the comparison of HE4 and CA125
in relation to recurrent disease, we showed that HE4
was superior to CA125 in the detection of recurrent dis-
ease. These findings are in accordance with previously
published studies.13,14 With comparable cut-off values,
Brennan et al. found an elevated HE4 in 80% of the
recurrences, whereas CA125 was elevated in only 47%.
Yet, those 26 patients with recurrent disease in this
study cohort (n=98) consisted mainly of patients with
local recurrence (n=20) and only few (n=6) with dis-
tant recurrences. On the contrary, our cohort contained
mainly distant recurrences (60%) where median HE4
values of distant recurrences were borderline significant
compared to serum values of local recurrences
(p=0.058).27,28
HE4 concentrations at time of the recurrence were
higher than at primary diagnosis. This finding is con-
flicting with literature.13,14 Angioli et al. and Brennan
et al. found no significant difference in HE4 concentra-
tion at primary diagnosis and recurrence. This might be
explained by the difference in study populations; as out-
lined above, our cohort contained less local recurrences
and more distant recurrences. A possible explanation is
that HE4 levels are associated with an increased
metastasis-associated tumor burden. The relationship
of HE4 concentration and tumor burden is described in
patients with ovarian cancer where HE4 levels were cor-
related with the presence of tumor burden after optimal
and suboptimal cytoreductive surgery.34 However, so
far, data about the relationship of HE4 serum levels
and tumor burden in EC patients are still lacking.
Serum levels of HE4 detected a recurrence with a
median of 126days before clinical confirmation which
implies that HE4 is a more sensitive and useful tumor
marker for detecting a recurrence during follow-up
than CA125. HE4 might be more specifically related to
the amount of tumor tissue when compared to CA125.
This finding is supported by a study conducted in ovar-
ian cancer patients where HE4 detected a recurrence
4.5months earlier than CA125.21 Patients who devel-
oped recurrent disease, especially those with distant
recurrences, were more likely to have an advanced
FIGO stage, a high tumor grade, and LVSI, which is in
concordance with literature.35–37 Our study shows that
high-risk patients are prone to develop distant metasta-
sis, and therefore, we suggest that their follow-up could
be improved by serial measurements of HE4 to detect
early recurrent disease. Whether earlier detection of
recurrent disease will contribute to an improved out-
come needs to be determined.
This study is the first to analyze dynamic changes of
HE4 during the follow-up period of EC patients. All
serum samples were managed in a standardized fash-
ion. Histology was performed by an expert gynecologic
pathologist. However, some limitations need to be
addressed. Serum of patients was stored over a long
timeframe and possible influences on the HE4 protein
cannot be ruled out. However, repeated measurements
of CA125 remained stable after years of storage and
did not significantly change. The selection of our study
cohort was based on the availability of consecutive
serum samples, and hence, this might result in selection
bias of our study population. In this study, we used
cut-off values of 70 pmol/L and 35U/mL for HE4 and
CA125, respectively. However, the cut-off level of
35U/mL for CA125 defines normal and pathological
serum levels for ovarian cancer, but for EC patients,
this has not been identified yet.29 Besides this, there is
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still an ongoing debate about the best cut-off for HE4
in the diagnostic work-up of EC. Cut-off levels of HE4
vary from 60 to 100pmol/L, but most studies used
70mmol/L because it yields the best sensitivity and spe-
cificity.20,28,30 In accordance with the analysis of
Capriglione et al.,31 we performed an ROC analysis of
HE4 and CA125 for the prediction of tumor stage.
Unfortunately, we could not confirm these findings nei-
ther for HE4 nor for CA125. This study reported HE4
cut-off levels for different tumor stages with high sensi-
tivity and specificity values. This could be explained by
the fact that our study cohort is different from the
study cohort of Capriglione et al. with more patients
with advanced-stage disease (30% vs 21%, respectively)
and more non-EC patients (22% vs 6%, respectively).
Furthermore, cut-off levels for detecting recurrent dis-
ease have not been identified yet and should be investi-
gated in future research.
A future prospective study on a larger cohort of
patients with EC is needed to affirm the preoperative
value of serum HE4 and the use of HE4 in routine fol-
low-up. Preoperative staging of patients with EC
remains challenging, and the promising data of HE4
could contribute to a more personalized approach in
EC patients. Currently, tumor histology, tumor grade,
MI, LVSI, and age are used to tailor treatment.
However, most of the prognostic risk factors are based
on final pathology, and therefore, an EC algorithm for
the identification of high-risk EC, based on preopera-
tive data, is urgently needed. The risk of endometrial
malignancy (REM) scoring system has recently been
validated to discriminate between benign disease and
EC with a high sensitivity and specificity. In addition,
this REM can differentiate between low- and high-risk
EC patients and hence contribute to tailor treat-
ment.38,39 Also imaging techniques combined with HE4
are used to assess the risk of MI, cervical involvement,
and lymph node involvement preoperatively in order to
modulate surgery.40 Interestingly, we also found that
HE4 significantly contributes to the prediction of
lymph node involvement with an AUC of 0.72 and a
sensitivity of 65% and specificity of 79% (cut-off value:
130mmol/L). Because there is an ongoing debate about
the therapeutic role of a lymphadenectomy, HE4 could
identify those patients who are at great risk of lymph
node involvement and helps planning the required sur-
gery. However, HE4 serum levels alone or in combina-
tion with other clinical features, histological features,
or imaging techniques could lead to a preoperative
algorithm to avoid under or overtreatment and sending
patients to specialized centers if necessary.
In conclusion, HE4 is correlated with histological
prognostic factors in EC and is a strong independent
prognostic factor for DFS and OS. Furthermore, HE4
shows to be superior in the detection of recurrent
disease during the follow-up period compared to
CA125, especially in high-risk EC developing distant
metastasis. Serum HE4 contributes to the preoperative
identification of low- and high-risk patients and could
therefore contribute to a more personalized treatment
and follow-up plan.
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